Date
|
Update
|
27 July 2023
|
Invitation to participate |
23 March 2023
|
Following the changes to remove technical engagement as standard from appraisal timelines, the timelines for the appraisal of Abaloparatide for treating osteoporosis in postmenopausal women have been revised. It is anticipated that the appraisal will begin in mid-July 2023 when we will write to you about how you can get involved. |
25 January 2023 - 22 February 2023
|
Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 882 |
25 January 2023
|
In progress. Scoping commencing |
17 June 2016
|
Suspended. For information abaloparatide will be appraised alongside raloxifene, teriparatide, denosumab and strontium ranelate [ID901] as a Multiple Technology Appraisal (MTA).
Further details regarding the timings of this MTA will be available in due course.
|
17 June 2016
|
Draft scope documents |